TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults~* CD4 count \> 250 cells/mm3~* Not presently receiving HIV antiretroviral therapy (\> 6 months or naïve)~* Viral load \> 3000 RNA copies/mL (3.5 log)~* No planned HIV anti-retroviral therapy for 8 weeks~Exclusion Criteria:~* Prior retinal eye disease~* CD4 \< 250 cells/µL~* Renal failure~* Active malignancy~* Corticosteroid therapy~* Age \< 18 or \> 65 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Chloroquine (Type: EXPERIMENTAL): Chloroquine 205mg or 500mg orally once daily (Results pooled)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Resuscitation in Patients Suffering From Burns Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥18 years of age~* 15%≥ Burn Total Body Surface Area Injury ≤60%~* Signed written informed consent from patient or legal representative~Exclusion Criteria:~* Patient age \>80 years~* Delay of patient randomisation \>8 hours post-burn~* Known pregnancy~* Known renal failure with oliguria or anuria not related to hypovolaemia (e.g. patients receiving dialysis treatment)~* High voltage electrical conduction injury~* Known severe liver disease~* Known fluid overload (hyperhydration), especially in cases of pulmonary oedema and congestive cardiac failure~* Intracranial bleeding (known active or suspicion of intracranial bleeding)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Volulyte (Type: EXPERIMENTAL): Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
- Human Serum Albumin (Type: ACTIVE_COMPARATOR): 5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Speech Locator_Benefits in Pediatric Popluations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Experienced (\> 6 months), full-time hearing aid user~* 10 years up to but not including 18 years of age~* Spoken English~* Ability to understand oral instruction~* Ability to describe listening experiences~* No known neurological issues or cognitive impairment~* Ability to attend the in-person appointment(s)~* No speech/language deficits that could compromising ability to perform tasks~* Healthy outer and middle ear~* Hearing loss consistent with fitting range of the investigational product~* Access to a smartphone that can be used during a home trial~* Informed consent (signature) of parent and consent or assent (verbal) of child~Exclusion Criteria:~* Clinical contraindications (e.g., closed ear canal, absence of pinna)~* Known hypersensitivity or allergy to materials comprising hear-ing aid or acoustic coupling~* Unwilling to wear the hearing aid~* Unwilling or not permitted to use a smartphone~* Aided open-set aided speech recognition scores for speech front (+15 dB SNR) \< 30%

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Audeo Lumity hearing aid with the SpeechSensor and StereoZoom 2.0 features (Type: EXPERIMENTAL): Audeo Lumity hearing aid and the SpeechSensor and StereoZoom 2.0 features, which is found in the Audeo Lumity devices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Treatment of Patients With Chronic Tinnitus With Repetitive Transcranial Magnetic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* chronic tinnitus (\> 6 months)~* at least moderate tinnitus distress~* no or consistent medication~* no or consistent Treatments~* residence in Germany and German speaking~Exclusion Criteria:~* objective tinnitus~* serious and not stable illness (e.g. acute psychosis, severe depression or substance dependence, epilepsy, brain tumor)~* meeting the contraindications for transcranial magnetic stimulation or magnetic resonance imaging (electric devices or metal implants in the body, e.g. cardiac pace maker, insulin pump)~* neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder, epilepsy, brain malformation, severe head trauma)~* addictive disorder with consumption in the last two years~* regular intake of benzodiazepines~* participation in another study parallel to the trial~* pregnancy or breastfeeding period~* psychiatric confinement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- individualized rTMS (Type: EXPERIMENTAL): Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
- standard rTMS in responders (Type: ACTIVE_COMPARATOR): Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
- standard rTMS in non-responders (Type: ACTIVE_COMPARATOR): Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Absolute neutrophil count \>= 1,500/mm3~* No psychiatric illness or social situation that would preclude study compliance~* Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and investigational or targeted therapies (i.e., inhibitors of the epidermal growth factor receptor) will not count toward the maximum of 2 prior regimens allowed~* Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or extrahepatic bile duct or gallbladder:~  * Locally advanced or metastatic disease~* At least 1 unidimensionally measurable lesion \>=20 mm by conventional techniques OR \>= 10 mm by spiral CT scan~* Not amenable to curative surgical resection~* No known brain metastases~* Performance status:~  * ECOG 0-2~* Life expectancy:~  * More than 12 weeks~* Platelet count \>= 100,000/mm3~* WBC \>= 3,000/mm3~* AST and ALT ≤ 2.5 times upper limit of normal (ULN) \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\]~* Bilirubin ≤ 1.5 times ULN \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\]~* Creatinine within ULN OR Creatinine clearance \>= 60 mL/min~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No symptomatic cardiac arrhythmia within the past 4 weeks~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No underlying neuropathy \>= grade 2~* No history of allergic reaction to boron, mannitol, or bortezomib~* No active or ongoing infection~* No concurrent uncontrolled illness~* No medical or psychiatric condition that would preclude study participation~* No prophylactic granulocyte or platelet growth factors (filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])~* Prior chemotherapy as a radiosensitizer (e.g., fluorouracil or gemcitabine) with radiotherapy is allowed as adjuvant therapy after resection for locally advanced disease provided there is evidence of disease progression~* No more than 2 prior chemotherapy regimens for locally advanced or metastatic disease~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent anticancer agents or therapies~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Longevity, Functional Status and Quality of Life of the Compress® Compliant Pre-Stress System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are/will be operated from 26/08/1999 onwards in UZ Leuven~* Implantation of the Compress Compliant Pre-Stress Device~* Informed consent obtained~* Patients are able to complete the questionnaires~* Age: minimum 7 years old~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective group (Type: OTHER): Patients who have to undergone the implant surgery
- Retrospective group (Type: OTHER): Patients that have already undergone the implant surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Immunotherapy for Food Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic, reproducible symptoms following meals.~2. Multiple food allergies where dietary avoidance is nearly impossible.~3. Patients age 4 and older.~4. Testing to verify food allergies is positive.~Exclusion Criteria:~1. History of anaphylaxis, angioedema, asthma, or life-endangering reactions to certain food products.~2. Children under the age of 4.~3. Previous attempts to treat food allergy (subcutaneous injections).~4. General medical condition that precludes elective therapy (including pregnancy).~5. Inability to follow food allergy SLIT regimen.~6. Autoimmune Disease.~7. Chronic use of steroids.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Food Drops (Type: NO_INTERVENTION): The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
- Food Drops (Type: ACTIVE_COMPARATOR): Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF~* Patients with elevated LCI of ≥ 7.5 at screening~* Patients with FEV1 of ≥ 50% predicted at screening~* Use of inhaled Tobramycin in a 28 days on / off regimen in the past 3 months before screening~* chronic lung Infection with Pseudomonas aeruginosa~Exclusion Criteria:~* Patients who are regularly receiving more than one class of inhaled anti-pseudomonal antibiotic~* Patients who have used oral or intravenous anti-pseudomonal antibiotics within 28 days prior to on-phase of study drug~* Pregnant or nursing (lactating) women~* Change in dose, formulation or strength of the study drug in the past treatment cycle before screening~* History of hearing loss or chronic tinnitus~* Infection with Burkholderia cenocepacia complex~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin ALL (Type: EXPERIMENTAL): 300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Routine Versus Selective Use of FFR to Guide PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with stable coronary artery disease or recent acute coronary syndrome (ACS). Subjects who present with ST elevation myocardial infarction (STEMI) are allowed to be included after 5 days from initial presentation.~2. At least one obstructive coronary lesion is present with vessel reference diameter ≥2.5 mm and diameter stenosis ≥50% by visual estimate. Lesions must be technically suitable for the FFR procedure and angioplasty with stent placement.~3. Physician will classify all target lesions and need for FFR before randomization, and there is a plan to perform a non-emergent PCI.~4. Subject is ≥18 years old, with signed informed consent.~Exclusion Criteria:~1. Expected non-cardiac longevity \< 2 years.~2. Planned treatment with CABG.~3. Planned treatment with medical therapy.~4. Left main disease \> 50% diameter stenosis based on visual estimate.~5. Safety issues:~   1. Unstable hemodynamics or serious arrhythmias during procedure;~  2. Ongoing ischemic chest pain;~  3. High grade AV block (unless pacemaker);~  4. Allergic to adenosine.~6. When FFR is clearly not needed:~   1. Target vessel with slow flow (\< TIMI-3);~  2. Single vessel disease with ≥90% stenosis;~  3. Single vessel disease with ≥80% stenosis and documented ischemia on functional imaging test;~  4. In acute coronary syndrome, ≥70 stenosis identified as culprit.~7. When FFR is clearly needed for all target lesions: as declared by the operator.~8. Technical difficulty:~   1. Severe vessel tortuosity;~  2. Severe coronary calcification;~  3. Anticipate difficult wiring;~  4. Aorto-ostial lesion (ok for IV adenosine is used as the hyperemic agent).~9. Interpretation difficulty:~   1. Target vessel acting as a major collateral donor;~  2. When RA pressure very high;~  3. STEMI within past 5 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine use of FFR (Type: EXPERIMENTAL): Fractional Flow Reserve (FFR) used in most cases to guide PCI
- Selective use of FFR (Type: ACTIVE_COMPARATOR): Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic criteria for post dural puncture headache~* Moderate to severe post dural puncture headache~Exclusion Criteria:~* Procedure failures: new dural puncture on epidural blood patch trial, unable to find epidural space, intolerance to insertion of nasal swabs.~* Follow up loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
- Control group (Type: ACTIVE_COMPARATOR): Patients will receive classic epidural blood patch with 20ml of autologous blood

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years old~* Able to consent~* Has cutaneous abscess less than or equal to 2 centimeters requiring incision and drainage in the Emergency Department~Exclusion Criteria:~* Less than 18 years old~* Unable to consent~* Pregnant or breastfeeding~* Prisoner or in police custody~* Known sensitivity to vapocoolant or lidocaine~* Cold hypersensitivity~* Chronic steroid use~* Peripheral neuropathy~* Diabetes~* HIV~* Malignancy~* Immunosuppressive state~* Sickle cell disease~* Sarcoidosis~* Abscess greater than 2 centimeters in any dimension~* Abscess requiring procedural sedation and analgesia for incision and drainage, or further intervention outside the Emergency Department~* Abscess located on the hands, feet, face, or perineal areas~* Pilonidal cyst~* hidradenitis suppurativa~* Not a good candidate per attending physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
- Vapocoolant (Type: ACTIVE_COMPARATOR): Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent~2. ≥ 18 years and ≤ 75 years~3. Good physical health (ASAI/II)~4. Extraction of maxillary premolar, canine or incisor, or mandibular premolar and canine required~5. Teeth adjacent (mesial and distal) to study site must consist of two stable natural teeth with minimal restorations, without signs of periodontal bone loss (\> 3 mm) and/or significant soft tissue deficiencies~Exclusion Criteria:~1. Buccal plate dehiscence and/or fenestration \>3mm at study site following extraction~2. Untreated rampant caries and uncontrolled periodontal disease~3. Inadequate oral hygiene (estimated plaque score \>20%)~4. Smokers using more than 10 cigarettes or equivalent per day~5. Smokeless tobacco use or e-cigarette use~6. Compromised physical health and/or uncontrolled or severe systemic diseases including:~   ASA III/IV Metabolic bone disease History of malignancy History or radiotherapy or chemotherapy for malignancy in the past 5 years History of autoimmune disease Long-term steroidal or antibiotic therapy Uncontrolled diabetes Known alcohol or drug abuse~7. Systemic or local disease or condition that would compromise post-operative healing~8. Use of any substance or medication that will influence bone metabolism~9. Known pregnancy~10. Unable or unwilling to return for follow-up visits for a period of 6 months~11. Unlikely to be able to comply with study procedures according to Investigators judgement~12. Involvement in the planning and conduct of the study~13. Previous enrollment or randomization of treatment in the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group A- Allograft, Membrane (Type: ACTIVE_COMPARATOR): Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
- Group B- Alloplast, Membrane (Type: ACTIVE_COMPARATOR): Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
- Group C- Xenograft, Membrane (Type: ACTIVE_COMPARATOR): OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
- Group D- Membrane (Type: ACTIVE_COMPARATOR): Symbios OsteoShield Collagen Resorbable Membrane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues